CNBX - Cannabics Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1640
+0.0049 (+3.08%)
As of 2:20PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1591
Open0.1600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1300 - 0.1650
52 Week Range0.0700 - 0.6100
Volume77,252
Avg. Volume681,076
Market Cap22.045M
Beta (5Y Monthly)-0.97
PE Ratio (TTM)N/A
EPS (TTM)-0.0250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Cannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids
    PR Newswire

    Cannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that its R&D; team in Israel studies the combinatorial effects of purified cannabinoids and has recently revealed complex relations between cannabinoid compounds, some of which bare synergistic effects and some antagonistic effects on the viability of gastrointestinal cancer cells.

  • PR Newswire

    Cannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it is offering its High Throughput Screening (HTS) facility, in order to assist with the Israeli national effort in researching and containing SARS-CoV-2.

  • Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma
    PR Newswire

    Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has completed a scan of selected RCKMC's cannabis strains. Results obtained have shown that two specific strains have demonstrated higher anti-tumor activity.

  • Cannabics Pharmaceuticals Reveals Different Extraction Methods Result in Differential Necrotic Effects of Cannabis on Gastrointestinal Cancer Cells
    PR Newswire

    Cannabics Pharmaceuticals Reveals Different Extraction Methods Result in Differential Necrotic Effects of Cannabis on Gastrointestinal Cancer Cells

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, released an update today regarding its pre-clinical studies held at the company's High Throughput Screening (HTS) facility in Israel.

  • Cannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form
    PR Newswire

    Cannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the cannabinoids CBN (Cannabinol) and CBC (Cannabichromene) and their acidic form were shown to have necrotic effects on human colon cancer cells in a pre-clinical study held at the company's High Throughput Screening (HTS) facility in Israel.

  • Cannabics Pharmaceuticals Collaborates With RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers
    PR Newswire

    Cannabics Pharmaceuticals Collaborates With RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has signed a Memorandum Of Understanding with RCK Medical Cannabis to develop cannabis chemovars targeted to treat gastro intestinal cancers.

  • Cannabics Pharmaceuticals Study Shows Cannabinoids CBC and CBG Exhibit
    PR Newswire

    Cannabics Pharmaceuticals Study Shows Cannabinoids CBC and CBG Exhibit

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that in a series of tests conducted at the company's High Through-put Screening (HTS) facility in Israel, it has been shown that the cannabinoids CBC (Cannabichromene) and CBG (Cannabigerol) both exhibit anti-tumor properties, tested on human Gastrointestinal Cancer Cells.

  • Cannabics Pharmaceuticals Announces Cannabigerol (CBG) Shown to Have Anti-tumor Properties
    PR Newswire

    Cannabics Pharmaceuticals Announces Cannabigerol (CBG) Shown to Have Anti-tumor Properties

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that in a pre-clinical study held at the company's High Throughput Screening (HTS) lab facilities in Israel, preliminary findings show that the cannabinoid Cannabigerol (CBG) was shown to have a greater anti-tumor effect on human stomach and bone cancer cell lines compared to CBGA, the acidic form of the compound.

  • Cannabics Pharmaceuticals Announces the Appointment of Dr. Yaakov Waksman as Head of Cannabidiol Research
    PR Newswire

    Cannabics Pharmaceuticals Announces the Appointment of Dr. Yaakov Waksman as Head of Cannabidiol Research

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that Dr. Yaakov Waksman is to join the company as Head of Cannabidiol Research.

  • Cannabics Pharmaceuticals Announces Publication of Clinical Data From Its Sponsored Pilot Study on Controlled Release Capsules, on the Journal of Integrative Cancer Therapies
    PR Newswire

    Cannabics Pharmaceuticals Announces Publication of Clinical Data From Its Sponsored Pilot Study on Controlled Release Capsules, on the Journal of Integrative Cancer Therapies

    Data Demonstrated Cannabics' SR capsules with 5 mg dosage seems to be appropriate for the treatment of cancer anorexia-cachexia syndrome (CACS) in advanced cancer patients under active treatment. TEL AVIV, Israel and BETHESDA, Maryland, Oct. 16, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the final results of its pilot study to test the efficacy of Cannabics' Dosage-Controlled capsules for the treatment of cancer anorexia-cachexia syndrome (CACS) in advanced cancer patients have been published on the Journal of Integrative Cancer Therapies.

  • Cannabics Pharmaceuticals Appoints Company's Founder to Its Board of Directors
    PR Newswire

    Cannabics Pharmaceuticals Appoints Company's Founder to Its Board of Directors

    TEL AVIV, Israel and BETHESDA, Maryland, Oct. 7, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid based cancer medicine, today announced that it has appointed the Company's Founder as a new Director and Member of its Board. Itamar Borochov, 62, is an environmentalist with vast experience as an entrepreneur in the medical cannabis field, with broad experience in management and finance in medical cannabis companies which operate in regulated markets. Mr. Borochov was the original Founder of Cannabics Pharmaceuticals Inc.

  • Cannabics Pharmaceuticals to Present Research Data at the 2nd International Cannabinoid Derived Pharmaceuticals Summit in Boston, MA
    PR Newswire

    Cannabics Pharmaceuticals to Present Research Data at the 2nd International Cannabinoid Derived Pharmaceuticals Summit in Boston, MA

    TEL AVIV, Israel and BETHESDA, Maryland, Sept. 12, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabis based cancer medicine, today announced that its Scientific Director, Dr. Ilan Hochman, is scheduled to present research data from cannabinoid tests on live cancer biopsies at the 2nd  International Cannabinoid Derived Pharmaceuticals Summit, to be held in Boston, MA, on September 10-12, 2019. The company has been focusing on developing solutions for bringing cannabis based solutions into the mainstream of cancer treatments together with existing therapeutic approaches.

  • Benzinga

    'Algorithms Manage Everything': One Israeli Company's Mission To Make Marijuana Growing Effortless

    Cannabis cultivation is a meticulous process that involves more than just planting a seed or a clone and watering it regularly. Luckily, there are solutions that make growing weed easier, even in the comfort of one’s home. One of these solutions is Seedo, a special pod that takes care of the entire growing process and can be controlled through an app on a smartphone.

  • Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments
    PR Newswire

    Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments

    HOD HASHARON, Israel, June 28, 2019 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that the Company and Cannabics Pharmaceuticals (CNBX) have together created and adopted a business plan for their joint venture (JV), a new entity focused on the research and development of cannabinoid formulations to treat ophthalmic conditions. Creation and approval of a business plan for the JV was a condition for the planned venture to move forward. Having assessed the regulatory pathway for eyedrops containing cannabinoids or cannabinoid strings, we are eagerly engaging in technology development and clinical advancement.

  • /C O R R E C T I O N -- Cannabics Pharmaceuticals Inc./
    PR Newswire

    /C O R R E C T I O N -- Cannabics Pharmaceuticals Inc./

    In the news release, Cannabics Pharmaceuticals Appoints Two Independent Directors, issued June 25, 2019 by Cannabics Pharmaceuticals Inc. over PR Newswire, we are advised by the company that the 5th paragraph, 1st sentence, should read "Mr. Ballan served as Senior Executive Vice President and General Counsel at Gazit Globe, a Tel Aviv Stock Exchange listed company that is part of the TA-35 and Real-Estate 15 indexes in Israel." rather than as originally issued inadvertently. TEL AVIV, Israel and BETHESDA, Maryland, June 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has appointed two new independent directors to its board of directors, Dr. Estery Giloz-Ran and Eran Ballan, Esq.

  • Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada
    PR Newswire

    Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada

    TEL AVIV, Israel and BETHESDA, Maryland, June 4, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be participating at the LIFT & Co. Conference at the Metro Toronto Convention Centre in Toronto, Canada. "This year's conference in Toronto is exciting because it is the largest premier industry business conference event in Canada," stated Mr. Barad.

  • ACCESSWIRE

    Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California

    TEL AVIV, ISRAEL and BETHESDA, MD / ACCESSWIRE / May 30, 2019 / Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4 at 11:20AM PST at the Luxe Sunset Hotel in Bel Air, California. Mr. Eyal Barad (CEO of Cannabics Pharmaceuticals) will be presenting and meeting with investors. "This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges," stated Chris Lahiji, President at LD Micro.

  • Cannabics Pharmaceuticals' CEO to Present at the Planet MicroCap Conference in Las Vegas and at the ThinkEquity Conference in New York City
    PR Newswire

    Cannabics Pharmaceuticals' CEO to Present at the Planet MicroCap Conference in Las Vegas and at the ThinkEquity Conference in New York City

    TEL AVIV, Israel and BETHESDA, Maryland, April 25, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, CEO, is scheduled to present at the Planet Microcap Conference in Las Vegas, Nevada, being held at the Bally's Hotel, and at the ThinkEquity Conference in New York City being held at The Mandarin Oriental Hotel. Mr. Barad is scheduled to present at the Planet MicroCap conference in Las Vegas at 2pm Pacific Time on May 1, 2019. Mr. Barad will also be speaking at the ThinkEquity conference, at 2pm Eastern Time, on May 2, 2019.

  • Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies
    PR Newswire

    Cannabics Pharmaceuticals Announces Initiation of a Nationwide Clinical Study to Evaluate Antitumor Properties of Cannabinoid Compounds on Primary Cancer Biopsies

    TEL AVIV, Israel and BETHESDA, Maryland, April 17, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has obtained approval for a nationwide Israeli multisite clinical study on the antitumor properties of cannabinoid compounds on primary cancer biopsies. The apoptotic/cytotoxic effects of a multitude of cannabinoid extracts will be evaluated via Cannabics' high throughput screening platform. Dr. Eyal Ballan, CTO and Co-Founder of Cannabics, said: "We believe this is a quantum leap for the research on the biology of cancer and cannabinoids.